Australian Clinical Labs Ltd (ASX: ACL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Australian Clinical Labs Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Australian Clinical Labs Ltd (ASX: ACL)
Latest News
Healthcare Shares
Why is this ASX 300 healthcare stock up more than 17%?
Healthcare Shares
Australian Clinical Labs delivers profit growth and stronger margins in FY26
Dividend Investing
32 ASX shares about to go ex-dividend
Share Fallers
Why Audinate, Australian Clinical Labs, Coronado, and Treasury Wine shares are sinking today
Healthcare Shares
Australian Clinical Labs shares hit record low as CEO to exit
Opinions
2 ASX All Ords shares I'd buy today
Healthcare Shares
Macquarie predicts this ASX All Ords healthcare stock to surge past $1 billion over the next 12 months
Small Cap Shares
Why I think this ASX small-cap stock is a bargain at $2.70
Mergers & Acquisitions
Macquarie names 16 potential ASX takeover targets
Share Gainers
Why Australian Clinical Labs, Karoon Energy, MA Financial, and Silex shares are roaring higher today
Healthcare Shares
Major buyback at pathology provider has shares heading north
52-Week Lows
3 popular ASX shares trading close to 52 week lows
Frequently Asked Questions
-
Yes, Australian Clinical Labs has historically paid two fully franked shareholder dividends a year.
-
Australian Clinical Labs generally pays its shareholder dividends in April and September.
-
Australian Clinical Labs Ltd listed on the ASX on 14 May 2021.
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 02 Sep 2026 | $0.0925 | 100.00% | Final | 23 Sep 2026 |
| 12 Mar 2026 | $0.0375 | 100.00% | Interim | 31 Mar 2026 |
| 01 Sep 2025 | $0.0900 | 100.00% | Final | 23 Sep 2025 |
| 27 Mar 2025 | $0.0350 | 100.00% | Interim | 16 Apr 2025 |
| 04 Sep 2024 | $0.0900 | 100.00% | Final | 27 Sep 2024 |
| 28 Mar 2024 | $0.0300 | 100.00% | Interim | 26 Apr 2024 |
| 27 Mar 2023 | $0.0700 | 100.00% | Interim | 26 Apr 2023 |
| 23 Aug 2022 | $0.4100 | 100.00% | Final | 15 Sep 2022 |
| 25 Mar 2022 | $0.1200 | 100.00% | Interim | 21 Apr 2022 |
ACL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Australian Clinical Labs Ltd
Australian Clinical Labs Ltd (ASX: ACL) is a leading provider of pathology services in Australia. The company's 75 laboratories perform more than 12 million episodes annually with a network of more than 1,300 collection centres in every Australian state and territory except Tasmania. The company is also among the largest private hospital pathology businesses in the country, providing services to more than 90 private and public hospitals.
Its services include all routine pathology tests, advanced pathology, pregnancy screening, non-invasive prenatal testing, chemical pathology, haematology, histopathology, immunology, serology and microbiology, and commercial drug and alcohol testing.
In ACL's established regions of Western Australia, Victoria, New South Wales, Queensland, South Australia, and the Northern Territory, the company has an equivalent market position in community pathology to its rivals Sonic Healthcare Ltd (ASX: SHL) and Healius Ltd (ASX: HLS). The company says it also has a growing presence in the Australian Capital Territory.
ACL Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 11 Sep 2026 | $2.73 | $-0.03 | -1.09% | 295,622 | $2.76 | $2.78 | $2.70 |
| 10 Sep 2026 | $2.76 | $-0.04 | -1.43% | 341,867 | $2.76 | $2.80 | $2.73 |
| 09 Sep 2026 | $2.80 | $0.03 | 1.08% | 716,699 | $2.79 | $2.83 | $2.76 |
| 08 Sep 2026 | $2.77 | $0.00 | 0.00% | 270,276 | $2.77 | $2.79 | $2.74 |
| 07 Sep 2026 | $2.77 | $0.02 | 0.73% | 342,275 | $2.75 | $2.79 | $2.72 |
| 04 Sep 2026 | $2.75 | $0.04 | 1.48% | 518,324 | $2.70 | $2.75 | $2.69 |
| 03 Sep 2026 | $2.71 | $0.00 | 0.00% | 445,629 | $2.71 | $2.74 | $2.70 |
| 02 Sep 2026 | $2.71 | $-0.09 | -3.21% | 406,279 | $2.65 | $2.76 | $2.63 |
| 01 Sep 2026 | $2.80 | $0.02 | 0.72% | 461,939 | $2.78 | $2.81 | $2.76 |
| 31 Aug 2026 | $2.78 | $-0.02 | -0.71% | 516,049 | $2.80 | $2.82 | $2.77 |
| 28 Aug 2026 | $2.80 | $-0.02 | -0.71% | 502,796 | $2.84 | $2.88 | $2.76 |
| 27 Aug 2026 | $2.82 | $-0.04 | -1.40% | 1,230,721 | $2.87 | $3.03 | $2.79 |
| 26 Aug 2026 | $2.86 | $-0.11 | -3.70% | 1,390,275 | $2.97 | $2.97 | $2.84 |
| 25 Aug 2026 | $2.97 | $-0.02 | -0.67% | 744,807 | $2.98 | $3.00 | $2.95 |
| 24 Aug 2026 | $2.99 | $0.03 | 1.01% | 1,460,141 | $2.97 | $3.03 | $2.94 |
| 21 Aug 2026 | $2.96 | $0.07 | 2.42% | 1,154,255 | $2.89 | $2.98 | $2.86 |
| 20 Aug 2026 | $2.89 | $0.04 | 1.40% | 707,895 | $2.84 | $2.89 | $2.79 |
| 19 Aug 2026 | $2.85 | $0.01 | 0.35% | 1,234,404 | $2.84 | $2.86 | $2.78 |
| 18 Aug 2026 | $2.84 | $0.14 | 5.19% | 2,164,608 | $2.71 | $2.85 | $2.71 |
| 17 Aug 2026 | $2.70 | $0.35 | 14.89% | 5,945,671 | $2.45 | $2.86 | $2.45 |
| 14 Aug 2026 | $2.35 | $-0.01 | -0.42% | 482,373 | $2.37 | $2.39 | $2.33 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 19 Feb 2026 | Sarah Butler | Buy | 22,617 | $49,983 |
On-market trade. Average consideration of $2.21 per share
|
| 28 Oct 2025 | Stephen Roche | Buy | 70,000 | $193,900 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Stephen Patrick Roche | Non-Executive DirectorNon-Executive Chairman | Jun 2025 |
Mr Roche has strategic and operational experience across several industry sectors including healthcare, retail, building materials and fast-moving consumer goods. Stephen has over 15 years' experience as a director of public companies, not-for-profits and private family offices, having held executive roles as the Managing Director and CEO of Australian Pharmaceutical Industries Limited and Bridgestone Australia & New Zealand. Stephen is currently a Director of the Adelaide Football Club. Stephen was formerly a Non-Executive Director of Myer Family Investments Ltd. He also established and was Chair of the Priceline Sisterhood Foundation from 2015, before retiring in 2018. The foundation, with its mission of creating positive health outcomes and support for women, became the official charity for all Wesfarmers Health businesses from 2025.
|
| Ms Christine Nildra Bartlett | Non-Executive Director | Aug 2023 |
Ms Bartlett is an experienced Non-Executive Director, with executive experience gained through chief executive officer and senior executive roles with National Australia Bank Limited, IBM and Jones Lang LaSalle. Christine has held roles with national and global responsibilities and has a commercial perspective, in fostering innovation and leveraging new emerging technologies. Christine is currently the Chair of CEDA and a Non-Executive Director of Mirvac Limited, TAL Life Limited and Reliance Worldwide Corporation Limited. Christine is a member of the UNSW Australian School of Business Advisory Council. Christine has previously held Non-Executive Director roles with iCare NSW, Clayton Utz, GBST Holdings Limited, The Smith Family and Sigma Healthcare Limited. She is member of Risk Committee.
|
| Mr Mark Haberlin | Non-Executive Director | Apr 2021 |
Mr Haberlin has over 25 years of audit, risk management, capital transactions and mergers and acquisitions experience across industries including healthcare, real estate and financial services. Mark is the Lead Independent Director and Chair of the Audit and Risk Committee of Abacus Property Group. Previously, Mark was an independent Non-Executive Director and the Chair of the Audit and Risk Committee of Laybuy Group Holdings Limited, the Chair of PwC Australia and PwC's Public Reporting Panel, as well as a Director of the European Australia Business Council and PwC Asia Pacific. He is chair of Risk Committee.
|
| Ms Sarah Butler | Non-Executive Director | Feb 2025 |
Ms Butler has experience in health, insurance, government, consumer and technology industries with a long career in strategy consulting with Booz & Company and subsequently at PwC. Sarah has worked as a strategic advisor in more than 30 countries, including five years spent living and working in China and Asia. Sarah is currently a Non-Executive Director of Lumonus (global healthtech), Insurance Manufacturers of Australia (being a joint venture of IAG and RACV) and The George Institute for Global Health, where she is also the Chair of the People Committee.
|
| Mr Greg John Horan | Chief Executive OfficerExecutive Director | Aug 2026 |
Mr. Horan was most recently CEO of Healthscope, during a period of unprecedented industry change as the private hospital sector emerged from the COVID pandemic. He was accountable for the day-to-day performance of the Healthscope business and its strategic direction, leading its 20,000 employees and 5000 visiting medical officers across 43 hospitals. Mr. Horan started his career in the mining industry before moving into private equity with Brookfield Capital Partners. He has 25 years of experience across a range of industries, consistently translating strategy into operational execution through the empowerment of people, clear accountability of outcomes and an action-oriented mindset.
|
| Dr Amandeep Kaur Hansra | Non-Executive Director | Jul 2026 |
Dr Hansra is a General Practitioner with more than 20 years clinical experience and whose career has included clinical practice, national digital health leadership, government engagement and a number of board roles. In her executive career, Dr Hansra has held the roles of Chief Medical Officer with Telstra Health, Head of Clinical Innovation at NIB and Deputy Chief Medical Officer at the Department of Home Affairs. Dr Hansra has led national clinical governance frameworks across digital health, telehealth and technology-enabled care, including managing incidents and clinician engagement in emerging models of care. Dr Hansra remains committed to her GP practice as a Fellow of the Royal Australian College of General Practitioners and acts a Chief Clinical Advisor to the Australian Digital Health Agency. Dr Hansra is currently a non executive director of Healthicare, ACHS International, MoleMap New Zealand, Healthengine and the Central and Eastern Sydney Primary Health Network. Dr Hansra also serves as a member of the Industry Growth Committee for the Department of Industry, Science and Resources.
|
| Ms Eleanor Padman | Company Secretary |
-
|
|
| Matthew Cordingley | Chief Financial Officer |
-
|
|
| Eleanor Padman | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Citicorp Nominees Pty Limited | 56,401,782 | 28.81% |
| HSBC Custody Nominees (Australia) Limited | 49,496,460 | 25.28% |
| J P Morgan Nominees Australia Pty Limited | 31,611,161 | 16.15% |
| BNP Paribas Nominees Pty Ltd | 5,010,540 | 2.56% |
| National Nominees Limited | 2,969,871 | 1.52% |
| UBS Nominees Pty Limited | 2,670,859 | 1.36% |
| Melinda McGrath | 2,173,867 | 1.10% |
| Neweconomy Com Au Nominees Pty Limited | 2,144,321 | 1.10% |
| BNP Paribas Nominees Pty Ltd i | 1,508,979 | 0.77% |
| Warbont Nominees Pty Ltd | 1,469,081 | 0.75% |
| Merrill Lynch (Australia) Nominees Pty Limited | 1,421,218 | 0.73% |
| Ecapital Nominees Pty Limited | 1,352,591 | 0.70% |
| ACL Employee Share Trusco Pty Ltd | 1,268,956 | 0.65% |
| HSBC Custody Nominees (Australia) Limited i | 836,267 | 0.43% |
| Zachary Investments Pty Ltd | 800,000 | 0.41% |
| Anthony Friedli | 754,390 | 0.39% |
| A.C.N. 633 176 100 Pty Ltd | 749,464 | 0.38% |
| HSBC Custody Nominees (Australia) Limited GSI EDA | 612,905 | 0.31% |
| HSBC Custody Nominees (Australia) Limited Gsco Eca | 572,267 | 0.29% |
| Pacific Custodians Pty Limited | 550,845 | 0.28% |